Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IACT

Financiado

Cerrado

Immunostimulatory Agonist antibodies for Cancer Therapy

"This concerted action aims at providing new treatment options for cancer patients through boosting innovative drug development by European academia and industry. A wealth of preclinical data shows that the therapeutic impact of c... ver más

31/10/2017

GERMAN CANCER RESE...

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 9 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-10-31 No tenemos la información de la convocatoria

0% 73% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

9 Participantes

GERMAN CANCER RESEARCH CENTE...

0.00€ | Lider

BioNTech RNA

N.D. | Participante

FUNOACION PARA LA INVESTIG

N.D. | Participante

Proyectos interesantes

ONCO-BOOST

Medical Technol...

Biotechnology

71K€ Cerrado

ADC

Medical Technol...

Biotechnology

71K€ Cerrado

STI-001

Medical Technol...

Biotechnology

71K€ Cerrado

CTQ2016-78454-C2-1-R

Medical Technol...

Biotechnology

149K€ Cerrado

CTQ2016-78454-C2-2-R

Medical Technol...

Biotechnology

47K€ Cerrado

SAF2015-63007-CIN

Medical Technol...

Pharmaceuticals

11K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "This concerted action aims at providing new treatment options for cancer patients through boosting innovative drug development by European academia and industry. A wealth of preclinical data shows that the therapeutic impact of cytotoxic regimens is enhanced by simultaneous application of drugs that strengthen the immune system. The recent FDA-approval of Ipilimumab demonstrated that cancer immunotherapeutics constitute a clinically effective, marketable drug concept. Ipilimumab is an antagonist immunostimulatory antibody (IS-Ab) that removes the restraint on the immune response by blocking inhibitory receptors on immune cells. Potent immunity can also be elicited by means of agonist IS-Abs that engage activatory receptors. Our program will translate the agonist IS-Ab concept into clinical treatments. This is critical, because a repertoire of complementary drugs that act at different points in the immune regulatory network will be required to counter immune failure in different cancer (sub-)types. Our initiative is supported by longstanding experience as well as by the availability of clinical lead Abs. Pivotal are two clinical trials in which cancer type and treatment regimen have been selected to approximate pre-clinical settings in which striking therapeutic impact with agonist IS-Abs has been obtained. These studies will involve extensive analysis of efficacy-related biomarkers by means of validated assays, not only in blood samples, but also in the most relevant compartment: the tumor microenvironment. While our state-of-the-art agonist IS-Abs are being tested in the clinic, a parallel SME-driven effort will aim at the development of 2nd generation agonist IS-Abs with superior therapeutic index. This innovation is supported by proprietary technology and will result in intellectual property and marketable drugs. Taken together, our interdisciplinary platform is designed to yield maximal benefit for health care, academia and health-related industries in Europe."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores